Despite past growth, the company's predicted growth falls short of market expectations. With a similar P/E ratio to the market but weaker anticipated earnings, investors may face disappointments if the P/E aligns with growth outlook.

Due to consistent EPS growth, Shenzhen New Industries Biomedical Engineering appears promising for growth investors, fostering insider confidence. Despite 2 potential warning signs, further investigation for the stock's actual value is advised.